Literature DB >> 25805940

Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.

Gunnar Brandhorst1, Darinka Todorova Petrova1, Sebastian Weigand1, Christoph Eberle1, Nicolas von Ahsen1, Jessica Schmitz1, Frank Christian Schultze1, Dirk Raddatz1, Michael Karaus1, Michael Oellerich1, Philip D Walson1.   

Abstract

AIM: To compare the number of regulatory T-cells (Tregs) measured by flow cytometry with those obtained using a real-time quantitative PCR (qPCR) method in patients suffering from inflammatory bowel disease (IBD).
METHODS: Tregs percentages obtained by both flow cytometry and qPCR methods in 35 adult IBD patients, 18 out of them with Crohn´s disease (CD) and 17 with ulcerative colitis (UC) were compared to each other as well as to scores on two IBD activity questionnaires using the Harvey Bradshaw Index (HBI) for CD patients and the Simple Colitis Clinical Activity Index (SCCAI) for UC patients. The Treg percentages by flow cytometry were defined as CD4(+)CD25(high)CD127(low)FOXP3(+) cells in peripheral blood mononuclear cells, whereas the Treg percentages by qPCR method were determined as FOXP3 promoter demethylation in genomic DNA.
RESULTS: We found an average of 1.56% ± 0.78% Tregs by using flow cytometry, compared to 1.07% ± 0.53% Tregs by using qPCR in adult IBD patients. There were no significant correlations between either the percentages of Tregs measured by flow cytometry or qPCR and the HBI or SCCAI questionnaire scores in CD or UC patients, respectively. In addition, there was no correlation between Treg percentages measured by qPCR and those measured by flow cytometry (r = -0.06, P = 0.73; Spearman Rho). These data suggest that, either Treg-related immune function or the clinical scores in these IBD patients did not accurately reflect actual disease activity. Until the cause(s) for these differences are more clearly defined, the results suggest caution in interpreting studies of Tregs in various inflammatory disorders.
CONCLUSION: The two methods did not produce equivalent measures of the percentage of total Tregs in the IBD patients studied which is consistent with the conclusion that Tregs subtypes are not equally detected by these two assays.

Entities:  

Keywords:  Crohn´s disease; Inflammatory bowel disease; Method comparison; Regulatory T-cells; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25805940      PMCID: PMC4363763          DOI: 10.3748/wjg.v21.i11.3325

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  Quantification of circulating regulatory T cells by flow cytometry in kidney transplant patients after basiliximab induction therapy.

Authors:  Farida Abadja; Eric Alamartine; François Berthoux; Christophe Mariat; Christian Genin; Claude Lambert
Journal:  Transplantation       Date:  2010-02-15       Impact factor: 4.939

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 4.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

5.  Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue.

Authors:  Georg Wieczorek; Anne Asemissen; Fabian Model; Ivana Turbachova; Stefan Floess; Volker Liebenberg; Udo Baron; Diana Stauch; Katja Kotsch; Johann Pratschke; Alf Hamann; Christoph Loddenkemper; Harald Stein; Hans Dieter Volk; Ulrich Hoffmüller; Andreas Grützkau; Alexander Mustea; Jochen Huehn; Carmen Scheibenbogen; Sven Olek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

6.  CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.

Authors:  G Brandhorst; S Weigand; C Eberle; D Raddatz; M Karaus; M Oellerich; P D Walson
Journal:  Clin Chim Acta       Date:  2013-02-26       Impact factor: 3.786

7.  Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk.

Authors:  Nana-Maria Wagner; Gunnar Brandhorst; Frauke Czepluch; Mareike Lankeit; Christoph Eberle; Sebastian Herzberg; Vivien Faustin; Joachim Riggert; Michael Oellerich; Gerd Hasenfuss; Stavros Konstantinides; Katrin Schäfer
Journal:  Obesity (Silver Spring)       Date:  2013-03       Impact factor: 5.002

8.  Generation and function of induced regulatory T cells.

Authors:  Erica G Schmitt; Calvin B Williams
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

9.  In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells.

Authors:  Veera Hölttä; Taina Sipponen; Mia Westerholm-Ormio; Harri M Salo; Kaija-Leena Kolho; Martti Färkkilä; Erkki Savilahti; Outi Vaarala; Paula Klemetti
Journal:  ISRN Gastroenterol       Date:  2012-06-14

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.